nodes	percent_of_prediction	percent_of_DWPC	metapath
Bisacodyl—GPR55—GPCRs, Other—SSTR2—pancreatic cancer	0.0301	0.0461	CbGpPWpGaD
Bisacodyl—GPR55—GPCRs, Other—CCKBR—pancreatic cancer	0.029	0.0445	CbGpPWpGaD
Bisacodyl—Haematochezia—Erlotinib—pancreatic cancer	0.0198	0.0592	CcSEcCtD
Bisacodyl—Haematochezia—Sunitinib—pancreatic cancer	0.0171	0.0513	CcSEcCtD
Bisacodyl—GPR55—GPCRs, Other—CNR1—pancreatic cancer	0.0158	0.0242	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—SSTR3—pancreatic cancer	0.0153	0.0234	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—SSTR1—pancreatic cancer	0.0146	0.0224	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—PPY—pancreatic cancer	0.0143	0.022	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—PRLHR—pancreatic cancer	0.0143	0.0219	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—SSTR2—pancreatic cancer	0.0141	0.0216	CbGpPWpGaD
Bisacodyl—GPR55—pancreas—pancreatic cancer	0.0132	1	CbGeAlD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—SSTR3—pancreatic cancer	0.0121	0.0186	CbGpPWpGaD
Bisacodyl—Abdominal cramps—Tamoxifen—pancreatic cancer	0.0119	0.0357	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—SSTR1—pancreatic cancer	0.0116	0.0178	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—PPY—pancreatic cancer	0.0114	0.0175	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—SSTR2—pancreatic cancer	0.0112	0.0172	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—PRLHR—pancreatic cancer	0.0109	0.0167	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CCKBR—pancreatic cancer	0.0108	0.0166	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—CNR2—pancreatic cancer	0.0103	0.0158	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—SSTR3—pancreatic cancer	0.00924	0.0142	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—SSTR1—pancreatic cancer	0.00886	0.0136	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—PPY—pancreatic cancer	0.00869	0.0133	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—SSTR2—pancreatic cancer	0.00853	0.0131	CbGpPWpGaD
Bisacodyl—Abdominal cramps—Irinotecan—pancreatic cancer	0.00843	0.0252	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CCK—pancreatic cancer	0.00841	0.0129	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CCKBR—pancreatic cancer	0.00823	0.0126	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CNR2—pancreatic cancer	0.00819	0.0126	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CCKAR—pancreatic cancer	0.00806	0.0124	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—SST—pancreatic cancer	0.00801	0.0123	CbGpPWpGaD
Bisacodyl—Colitis—Erlotinib—pancreatic cancer	0.00766	0.0229	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—CNR1—pancreatic cancer	0.0074	0.0113	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—SCT—pancreatic cancer	0.00671	0.0103	CbGpPWpGaD
Bisacodyl—Haematochezia—Epirubicin—pancreatic cancer	0.00659	0.0197	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—CCK—pancreatic cancer	0.0064	0.00982	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—SST—pancreatic cancer	0.00637	0.00977	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CNR2—pancreatic cancer	0.00624	0.00957	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—GLP1R—pancreatic cancer	0.00624	0.00957	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CCKAR—pancreatic cancer	0.00614	0.00941	CbGpPWpGaD
Bisacodyl—Haematochezia—Doxorubicin—pancreatic cancer	0.00609	0.0182	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CNR1—pancreatic cancer	0.00588	0.00902	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—SHH—pancreatic cancer	0.0056	0.00858	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PRLHR—pancreatic cancer	0.00558	0.00855	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—IAPP—pancreatic cancer	0.00553	0.00847	CbGpPWpGaD
Bisacodyl—Colitis—Irinotecan—pancreatic cancer	0.00546	0.0163	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—AGTR1—pancreatic cancer	0.00542	0.00831	CbGpPWpGaD
Bisacodyl—Dehydration—Erlotinib—pancreatic cancer	0.00539	0.0161	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—PTHLH—pancreatic cancer	0.00531	0.00813	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—PTCH1—pancreatic cancer	0.00531	0.00813	CbGpPWpGaD
Bisacodyl—Cramp muscle—Tamoxifen—pancreatic cancer	0.00527	0.0158	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—SSTR3—pancreatic cancer	0.00522	0.008	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—GDI1—pancreatic cancer	0.00511	0.00784	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—GDI2—pancreatic cancer	0.00511	0.00784	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—SSTR1—pancreatic cancer	0.005	0.00767	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—PPY—pancreatic cancer	0.00491	0.00753	CbGpPWpGaD
Bisacodyl—Anorectal discomfort—Epirubicin—pancreatic cancer	0.00485	0.0145	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—SST—pancreatic cancer	0.00485	0.00744	CbGpPWpGaD
Bisacodyl—Abdominal discomfort—Tamoxifen—pancreatic cancer	0.00485	0.0145	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—SSTR2—pancreatic cancer	0.00482	0.00739	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—SSTR3—pancreatic cancer	0.00474	0.00727	CbGpPWpGaD
Bisacodyl—Dehydration—Sunitinib—pancreatic cancer	0.00466	0.0139	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—CCKBR—pancreatic cancer	0.00465	0.00713	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—SSTR1—pancreatic cancer	0.00454	0.00697	CbGpPWpGaD
Bisacodyl—Anorectal discomfort—Doxorubicin—pancreatic cancer	0.00449	0.0134	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—CNR1—pancreatic cancer	0.00448	0.00687	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PPY—pancreatic cancer	0.00446	0.00683	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—SSTR2—pancreatic cancer	0.00437	0.00671	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—GCG—pancreatic cancer	0.00433	0.00663	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—CCKBR—pancreatic cancer	0.00423	0.00648	CbGpPWpGaD
Bisacodyl—Abdominal discomfort—Sunitinib—pancreatic cancer	0.00415	0.0124	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—AGTR1—pancreatic cancer	0.00413	0.00633	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—GAST—pancreatic cancer	0.004	0.00613	CbGpPWpGaD
Bisacodyl—Dehydration—Irinotecan—pancreatic cancer	0.00384	0.0115	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—SCT—pancreatic cancer	0.00379	0.00582	CbGpPWpGaD
Bisacodyl—Colitis—Docetaxel—pancreatic cancer	0.00378	0.0113	CcSEcCtD
Bisacodyl—Cramp muscle—Irinotecan—pancreatic cancer	0.00372	0.0111	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—GAST—pancreatic cancer	0.00363	0.00557	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—CCK—pancreatic cancer	0.00362	0.00555	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—CNR2—pancreatic cancer	0.00353	0.00541	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—GLP1R—pancreatic cancer	0.00353	0.00541	CbGpPWpGaD
Bisacodyl—Malnutrition—Erlotinib—pancreatic cancer	0.00349	0.0104	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—CCKAR—pancreatic cancer	0.00347	0.00532	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—SCT—pancreatic cancer	0.00344	0.00528	CbGpPWpGaD
Bisacodyl—Muscle spasms—Tamoxifen—pancreatic cancer	0.00339	0.0101	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PRLHR—pancreatic cancer	0.00329	0.00505	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—CCK—pancreatic cancer	0.00329	0.00504	CbGpPWpGaD
Bisacodyl—Angioedema—Tamoxifen—pancreatic cancer	0.00322	0.00963	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—CNR2—pancreatic cancer	0.0032	0.00491	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—GLP1R—pancreatic cancer	0.0032	0.00491	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—CCKAR—pancreatic cancer	0.00315	0.00483	CbGpPWpGaD
Bisacodyl—Immune system disorder—Sunitinib—pancreatic cancer	0.00313	0.00937	CcSEcCtD
Bisacodyl—Syncope—Erlotinib—pancreatic cancer	0.00313	0.00935	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—IAPP—pancreatic cancer	0.00312	0.00479	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—CXCL8—pancreatic cancer	0.00312	0.00479	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—ACVR1B—pancreatic cancer	0.0031	0.00475	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—ZNRF3—pancreatic cancer	0.0031	0.00475	CbGpPWpGaD
Bisacodyl—Loss of consciousness—Erlotinib—pancreatic cancer	0.00307	0.00916	CcSEcCtD
Bisacodyl—Malnutrition—Sunitinib—pancreatic cancer	0.00302	0.00903	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—PTHLH—pancreatic cancer	0.003	0.0046	CbGpPWpGaD
Bisacodyl—Muscle spasms—Sunitinib—pancreatic cancer	0.0029	0.00868	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—SHH—pancreatic cancer	0.00287	0.0044	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—IAPP—pancreatic cancer	0.00284	0.00435	CbGpPWpGaD
Bisacodyl—Shock—Erlotinib—pancreatic cancer	0.0028	0.00837	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—SSTR3—pancreatic cancer	0.0028	0.00429	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—DTX1—pancreatic cancer	0.0028	0.00429	CbGpPWpGaD
Bisacodyl—Nervous system disorder—Erlotinib—pancreatic cancer	0.00279	0.00834	CcSEcCtD
Bisacodyl—Angioedema—Sunitinib—pancreatic cancer	0.00276	0.00825	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—SST—pancreatic cancer	0.00274	0.0042	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PTHLH—pancreatic cancer	0.00272	0.00417	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PTCH1—pancreatic cancer	0.00272	0.00417	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—SSTR1—pancreatic cancer	0.00268	0.00412	CbGpPWpGaD
Bisacodyl—Dehydration—Docetaxel—pancreatic cancer	0.00266	0.00794	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PPY—pancreatic cancer	0.00263	0.00404	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—SSTR2—pancreatic cancer	0.00258	0.00396	CbGpPWpGaD
Bisacodyl—Immune system disorder—Irinotecan—pancreatic cancer	0.00258	0.00771	CcSEcCtD
Bisacodyl—Cramp muscle—Docetaxel—pancreatic cancer	0.00257	0.00768	CcSEcCtD
Bisacodyl—Colitis—Epirubicin—pancreatic cancer	0.00255	0.00761	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—CNR1—pancreatic cancer	0.00253	0.00388	CbGpPWpGaD
Bisacodyl—Immune system disorder—Gemcitabine—pancreatic cancer	0.00251	0.00751	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CCKBR—pancreatic cancer	0.0025	0.00383	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—SST—pancreatic cancer	0.00249	0.00382	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.00248	0.00743	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.00248	0.00381	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.00246	0.00735	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—GCG—pancreatic cancer	0.00244	0.00375	CbGpPWpGaD
Bisacodyl—Shock—Sunitinib—pancreatic cancer	0.00242	0.00725	CcSEcCtD
Bisacodyl—Nervous system disorder—Sunitinib—pancreatic cancer	0.00242	0.00722	CcSEcCtD
Bisacodyl—Muscle spasms—Irinotecan—pancreatic cancer	0.00239	0.00715	CcSEcCtD
Bisacodyl—Colitis—Doxorubicin—pancreatic cancer	0.00236	0.00704	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.00235	0.00703	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—DTX4—pancreatic cancer	0.00235	0.0036	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—GLI1—pancreatic cancer	0.00235	0.0036	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—AGTR1—pancreatic cancer	0.00233	0.00357	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.00233	0.00696	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—CNR1—pancreatic cancer	0.0023	0.00352	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PPP2R5B—pancreatic cancer	0.00228	0.0035	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—NRP1—pancreatic cancer	0.00228	0.0035	CbGpPWpGaD
Bisacodyl—Abdominal pain—Tamoxifen—pancreatic cancer	0.00227	0.0068	CcSEcCtD
Bisacodyl—Abdominal pain—Erlotinib—pancreatic cancer	0.00225	0.00673	CcSEcCtD
Bisacodyl—Syncope—Irinotecan—pancreatic cancer	0.00223	0.00667	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—GCG—pancreatic cancer	0.00222	0.0034	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—HEY2—pancreatic cancer	0.0022	0.00337	CbGpPWpGaD
Bisacodyl—Loss of consciousness—Irinotecan—pancreatic cancer	0.00219	0.00653	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—GAST—pancreatic cancer	0.00215	0.00329	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00213	0.00636	CcSEcCtD
Bisacodyl—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00212	0.00634	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—AGTR1—pancreatic cancer	0.00212	0.00325	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—HEY1—pancreatic cancer	0.00203	0.00312	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—SCT—pancreatic cancer	0.00203	0.00312	CbGpPWpGaD
Bisacodyl—Anaphylactic shock—Irinotecan—pancreatic cancer	0.00203	0.00607	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.00202	0.00602	CcSEcCtD
Bisacodyl—Shock—Irinotecan—pancreatic cancer	0.002	0.00597	CcSEcCtD
Bisacodyl—Nervous system disorder—Irinotecan—pancreatic cancer	0.00199	0.00595	CcSEcCtD
Bisacodyl—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.00198	0.00591	CcSEcCtD
Bisacodyl—Diarrhoea—Tamoxifen—pancreatic cancer	0.00197	0.00588	CcSEcCtD
Bisacodyl—Abdominal pain—Sunitinib—pancreatic cancer	0.00195	0.00582	CcSEcCtD
Bisacodyl—Diarrhoea—Erlotinib—pancreatic cancer	0.00195	0.00582	CcSEcCtD
Bisacodyl—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.00194	0.00581	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CCK—pancreatic cancer	0.00194	0.00298	CbGpPWpGaD
Bisacodyl—Nervous system disorder—Gemcitabine—pancreatic cancer	0.00194	0.0058	CcSEcCtD
Bisacodyl—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00191	0.0057	CcSEcCtD
Bisacodyl—Dizziness—Tamoxifen—pancreatic cancer	0.0019	0.00569	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CNR2—pancreatic cancer	0.00189	0.0029	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—GLP1R—pancreatic cancer	0.00189	0.0029	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CXCL8—pancreatic cancer	0.00189	0.0029	CbGpPWpGaD
Bisacodyl—Dizziness—Erlotinib—pancreatic cancer	0.00188	0.00563	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CCKAR—pancreatic cancer	0.00186	0.00285	CbGpPWpGaD
Bisacodyl—Vomiting—Tamoxifen—pancreatic cancer	0.00183	0.00547	CcSEcCtD
Bisacodyl—Hypersensitivity—Sunitinib—pancreatic cancer	0.00182	0.00543	CcSEcCtD
Bisacodyl—Vomiting—Erlotinib—pancreatic cancer	0.00181	0.00541	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—JAG2—pancreatic cancer	0.0018	0.00277	CbGpPWpGaD
Bisacodyl—Headache—Tamoxifen—pancreatic cancer	0.0018	0.00539	CcSEcCtD
Bisacodyl—Dehydration—Epirubicin—pancreatic cancer	0.00179	0.00535	CcSEcCtD
Bisacodyl—Immune system disorder—Docetaxel—pancreatic cancer	0.00178	0.00533	CcSEcCtD
Bisacodyl—Headache—Erlotinib—pancreatic cancer	0.00178	0.00533	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—MEN1—pancreatic cancer	0.00178	0.00273	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00175	0.00524	CcSEcCtD
Bisacodyl—Malnutrition—Docetaxel—pancreatic cancer	0.00172	0.00514	CcSEcCtD
Bisacodyl—Nausea—Tamoxifen—pancreatic cancer	0.00171	0.00511	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00171	0.0051	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—SHH—pancreatic cancer	0.0017	0.0026	CbGpPWpGaD
Bisacodyl—Nausea—Erlotinib—pancreatic cancer	0.00169	0.00505	CcSEcCtD
Bisacodyl—Diarrhoea—Sunitinib—pancreatic cancer	0.00169	0.00504	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—NOTCH4—pancreatic cancer	0.00169	0.00258	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00168	0.00502	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—IAPP—pancreatic cancer	0.00168	0.00257	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00166	0.00496	CcSEcCtD
Bisacodyl—Dehydration—Doxorubicin—pancreatic cancer	0.00166	0.00495	CcSEcCtD
Bisacodyl—Muscle spasms—Docetaxel—pancreatic cancer	0.00165	0.00494	CcSEcCtD
Bisacodyl—Dizziness—Sunitinib—pancreatic cancer	0.00163	0.00487	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PTHLH—pancreatic cancer	0.00161	0.00247	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PTCH1—pancreatic cancer	0.00161	0.00247	CbGpPWpGaD
Bisacodyl—Abdominal pain—Irinotecan—pancreatic cancer	0.0016	0.0048	CcSEcCtD
Bisacodyl—Vomiting—Sunitinib—pancreatic cancer	0.00157	0.00468	CcSEcCtD
Bisacodyl—Headache—Sunitinib—pancreatic cancer	0.00154	0.00461	CcSEcCtD
Bisacodyl—Syncope—Docetaxel—pancreatic cancer	0.00154	0.00461	CcSEcCtD
Bisacodyl—Loss of consciousness—Docetaxel—pancreatic cancer	0.00151	0.00452	CcSEcCtD
Bisacodyl—Hypersensitivity—Irinotecan—pancreatic cancer	0.0015	0.00447	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—SST—pancreatic cancer	0.00147	0.00226	CbGpPWpGaD
Bisacodyl—Nausea—Sunitinib—pancreatic cancer	0.00146	0.00438	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.00145	0.00222	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—JAG1—pancreatic cancer	0.00144	0.00221	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—NOTCH3—pancreatic cancer	0.00143	0.0022	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00143	0.00428	CcSEcCtD
Bisacodyl—Anaphylactic shock—Docetaxel—pancreatic cancer	0.0014	0.00419	CcSEcCtD
Bisacodyl—Diarrhoea—Irinotecan—pancreatic cancer	0.00139	0.00415	CcSEcCtD
Bisacodyl—Shock—Docetaxel—pancreatic cancer	0.00138	0.00413	CcSEcCtD
Bisacodyl—Nervous system disorder—Docetaxel—pancreatic cancer	0.00138	0.00411	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CNR1—pancreatic cancer	0.00136	0.00208	CbGpPWpGaD
Bisacodyl—Diarrhoea—Gemcitabine—pancreatic cancer	0.00135	0.00404	CcSEcCtD
Bisacodyl—Dizziness—Irinotecan—pancreatic cancer	0.00134	0.00401	CcSEcCtD
Bisacodyl—Diarrhoea—Fluorouracil—pancreatic cancer	0.00133	0.00398	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—PIK3CG—pancreatic cancer	0.00132	0.00202	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—GCG—pancreatic cancer	0.00131	0.00201	CbGpPWpGaD
Bisacodyl—Vomiting—Irinotecan—pancreatic cancer	0.00129	0.00386	CcSEcCtD
Bisacodyl—Dizziness—Fluorouracil—pancreatic cancer	0.00129	0.00384	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.00128	0.00196	CbGpPWpGaD
Bisacodyl—Headache—Irinotecan—pancreatic cancer	0.00127	0.0038	CcSEcCtD
Bisacodyl—Vomiting—Gemcitabine—pancreatic cancer	0.00126	0.00376	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—AGTR1—pancreatic cancer	0.00125	0.00192	CbGpPWpGaD
Bisacodyl—Headache—Gemcitabine—pancreatic cancer	0.00124	0.0037	CcSEcCtD
Bisacodyl—Vomiting—Fluorouracil—pancreatic cancer	0.00124	0.0037	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—STK11—pancreatic cancer	0.00123	0.00189	CbGpPWpGaD
Bisacodyl—Headache—Fluorouracil—pancreatic cancer	0.00122	0.00364	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.00121	0.00362	CcSEcCtD
Bisacodyl—Nausea—Irinotecan—pancreatic cancer	0.00121	0.0036	CcSEcCtD
Bisacodyl—Immune system disorder—Epirubicin—pancreatic cancer	0.0012	0.0036	CcSEcCtD
Bisacodyl—Nausea—Gemcitabine—pancreatic cancer	0.00117	0.00351	CcSEcCtD
Bisacodyl—Malnutrition—Epirubicin—pancreatic cancer	0.00116	0.00347	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—PIK3CD—pancreatic cancer	0.00116	0.00178	CbGpPWpGaD
Bisacodyl—Nausea—Fluorouracil—pancreatic cancer	0.00115	0.00345	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.00115	0.00343	CcSEcCtD
Bisacodyl—Muscle spasms—Epirubicin—pancreatic cancer	0.00112	0.00333	CcSEcCtD
Bisacodyl—Immune system disorder—Doxorubicin—pancreatic cancer	0.00111	0.00333	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.00111	0.0017	CbGpPWpGaD
Bisacodyl—Abdominal pain—Docetaxel—pancreatic cancer	0.00111	0.00332	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—SMAD4—pancreatic cancer	0.00108	0.00166	CbGpPWpGaD
Bisacodyl—Malnutrition—Doxorubicin—pancreatic cancer	0.00107	0.00321	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—CXCL8—pancreatic cancer	0.00107	0.00164	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—HES1—pancreatic cancer	0.00105	0.00162	CbGpPWpGaD
Bisacodyl—Syncope—Epirubicin—pancreatic cancer	0.00104	0.00311	CcSEcCtD
Bisacodyl—Hypersensitivity—Docetaxel—pancreatic cancer	0.00103	0.00309	CcSEcCtD
Bisacodyl—Muscle spasms—Doxorubicin—pancreatic cancer	0.00103	0.00308	CcSEcCtD
Bisacodyl—Loss of consciousness—Epirubicin—pancreatic cancer	0.00102	0.00305	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—PIK3CB—pancreatic cancer	0.00101	0.00155	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—CXCL8—pancreatic cancer	0.00097	0.00149	CbGpPWpGaD
Bisacodyl—Syncope—Doxorubicin—pancreatic cancer	0.000962	0.00288	CcSEcCtD
Bisacodyl—Diarrhoea—Docetaxel—pancreatic cancer	0.00096	0.00287	CcSEcCtD
Bisacodyl—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000947	0.00283	CcSEcCtD
Bisacodyl—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000943	0.00282	CcSEcCtD
Bisacodyl—Shock—Epirubicin—pancreatic cancer	0.000931	0.00278	CcSEcCtD
Bisacodyl—Nervous system disorder—Epirubicin—pancreatic cancer	0.000928	0.00277	CcSEcCtD
Bisacodyl—Dizziness—Docetaxel—pancreatic cancer	0.000928	0.00277	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—TERT—pancreatic cancer	0.000924	0.00142	CbGpPWpGaD
Bisacodyl—Vomiting—Docetaxel—pancreatic cancer	0.000892	0.00267	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—HIF1A—pancreatic cancer	0.000883	0.00135	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—TSC2—pancreatic cancer	0.000881	0.00135	CbGpPWpGaD
Bisacodyl—Headache—Docetaxel—pancreatic cancer	0.000879	0.00263	CcSEcCtD
Bisacodyl—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000876	0.00262	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—APOE—pancreatic cancer	0.000862	0.00132	CbGpPWpGaD
Bisacodyl—Shock—Doxorubicin—pancreatic cancer	0.000862	0.00258	CcSEcCtD
Bisacodyl—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000859	0.00257	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—KDR—pancreatic cancer	0.000845	0.0013	CbGpPWpGaD
Bisacodyl—Nausea—Docetaxel—pancreatic cancer	0.000834	0.00249	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000817	0.00244	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—NFKBIA—pancreatic cancer	0.000804	0.00123	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—NOTCH1—pancreatic cancer	0.000796	0.00122	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PIK3CG—pancreatic cancer	0.000778	0.00119	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—NRAS—pancreatic cancer	0.000778	0.00119	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000774	0.00231	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—EGF—pancreatic cancer	0.000769	0.00118	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000756	0.00226	CcSEcCtD
Bisacodyl—Abdominal pain—Epirubicin—pancreatic cancer	0.000748	0.00224	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000716	0.00214	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—EGFR—pancreatic cancer	0.000709	0.00109	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Epirubicin—pancreatic cancer	0.000697	0.00208	CcSEcCtD
Bisacodyl—Abdominal pain—Doxorubicin—pancreatic cancer	0.000692	0.00207	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PIK3CD—pancreatic cancer	0.000684	0.00105	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—PIK3CA—pancreatic cancer	0.000678	0.00104	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—KRAS—pancreatic cancer	0.00067	0.00103	CbGpPWpGaD
Bisacodyl—Diarrhoea—Epirubicin—pancreatic cancer	0.000648	0.00194	CcSEcCtD
Bisacodyl—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000645	0.00193	CcSEcCtD
Bisacodyl—Dizziness—Epirubicin—pancreatic cancer	0.000626	0.00187	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—PIK3CA—pancreatic cancer	0.000615	0.000944	CbGpPWpGaD
Bisacodyl—Vomiting—Epirubicin—pancreatic cancer	0.000602	0.0018	CcSEcCtD
Bisacodyl—Diarrhoea—Doxorubicin—pancreatic cancer	0.000599	0.00179	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PIK3CB—pancreatic cancer	0.000596	0.000914	CbGpPWpGaD
Bisacodyl—Headache—Epirubicin—pancreatic cancer	0.000593	0.00177	CcSEcCtD
Bisacodyl—Dizziness—Doxorubicin—pancreatic cancer	0.000579	0.00173	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CXCL8—pancreatic cancer	0.000573	0.000879	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—HRAS—pancreatic cancer	0.000569	0.000873	CbGpPWpGaD
Bisacodyl—Nausea—Epirubicin—pancreatic cancer	0.000562	0.00168	CcSEcCtD
Bisacodyl—Vomiting—Doxorubicin—pancreatic cancer	0.000557	0.00166	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—AKT1—pancreatic cancer	0.000554	0.000849	CbGpPWpGaD
Bisacodyl—Headache—Doxorubicin—pancreatic cancer	0.000549	0.00164	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CASP3—pancreatic cancer	0.000549	0.000841	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CCND1—pancreatic cancer	0.000534	0.000819	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CTNNB1—pancreatic cancer	0.000529	0.000811	CbGpPWpGaD
Bisacodyl—Nausea—Doxorubicin—pancreatic cancer	0.00052	0.00155	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—MMP9—pancreatic cancer	0.000518	0.000795	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PTEN—pancreatic cancer	0.000515	0.00079	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—AKT1—pancreatic cancer	0.000503	0.000771	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—SRC—pancreatic cancer	0.000478	0.000733	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—VEGFA—pancreatic cancer	0.000465	0.000714	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—STAT3—pancreatic cancer	0.000461	0.000707	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—NRAS—pancreatic cancer	0.00046	0.000705	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MYC—pancreatic cancer	0.000428	0.000657	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—TGFB1—pancreatic cancer	0.000427	0.000655	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—EGFR—pancreatic cancer	0.000419	0.000642	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—KRAS—pancreatic cancer	0.000396	0.000607	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PIK3CA—pancreatic cancer	0.000364	0.000557	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—TP53—pancreatic cancer	0.000352	0.000539	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—HRAS—pancreatic cancer	0.000336	0.000516	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—AKT1—pancreatic cancer	0.000297	0.000455	CbGpPWpGaD
